2016
A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke
Jensen KP, Smith AH, Herman AI, Farrer LA, Kranzler HR, Sofuoglu M, Gelernter J. A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke. Molecular Psychiatry 2016, 22: 242-249. PMID: 27067016, PMCID: PMC5390815, DOI: 10.1038/mp.2016.43.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack or African AmericanCadherinsDiagnostic and Statistical Manual of Mental DisordersFemaleGene Expression RegulationGenome-Wide Association StudyHumansMaleMultigene FamilyNicotinePolymorphism, Single NucleotideProtocadherinsRecurrenceSmokingSmoking CessationSubstance Withdrawal SyndromeTobacco Use DisorderWhite PeopleConceptsNicotine withdrawalSingle nucleotide polymorphismsNovel smoking cessation treatmentsAfrican AmericansSmoking cessation treatmentNicotine withdrawal symptomsOvernight smoking abstinenceEuropean American smokersFrontal cortex tissueΓ geneCessation treatmentTobacco smokingSmoking abstinenceWithdrawal symptomsAbstinent smokersAmerican smokersΓ gene expressionNicotine infusionSmoking urgesInfusion studiesSmokersMRNA expressionRisk allelesCortex tissueBrief questionnaire
2011
GABRA2 and KIBRA genotypes predict early relapse to substance use
Bauer LO, Covault J, Gelernter J. GABRA2 and KIBRA genotypes predict early relapse to substance use. Drug And Alcohol Dependence 2011, 123: 154-159. PMID: 22129841, PMCID: PMC3294190, DOI: 10.1016/j.drugalcdep.2011.11.004.Peer-Reviewed Original ResearchConceptsMonths of abstinenceDrug use problemsCognitive controlContribution of ageAbstinence violationDrug abuse problemsKIBRA genotypeUse problemsDepression symptomsDrug involvementSubstance useAbuse problemsTreatment settingsDrug useKIBRARisk of relapseFuture studiesGABRA2AbstinenceSmall samplesEthnic groupsANKK1Younger age
2009
Subtypes of major depression in substance dependence
Niciu MJ, Chan G, Gelernter J, Arias AJ, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR. Subtypes of major depression in substance dependence. Addiction 2009, 104: 1700-1709. PMID: 19681804, PMCID: PMC2980795, DOI: 10.1111/j.1360-0443.2009.02672.x.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultAge FactorsAnxiety DisordersBlack or African AmericanComorbidityData Interpretation, StatisticalDepressive Disorder, MajorFemaleHispanic or LatinoHumansInterview, PsychologicalLogistic ModelsMaleRecurrenceSocioeconomic FactorsSubstance-Related DisordersSuicide, AttemptedWhite PeopleYoung AdultConceptsMajor depressive episodeSubstance dependenceMDE subtypesDrug dependenceRelated clinical featuresPotential therapeutic implicationsSubstance use disordersAcademic medical centerGreater psychiatric severitySemi-Structured AssessmentClinical featuresDepressive episodeMajor depressionMedical CenterSecondary data analysisDepressive symptomsDiagnostic criteriaPsychiatric severityTherapeutic implicationsUse disordersSubtypesAnxiety disordersPsychiatric measuresCase-control genetic studyCommunity recruitment
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity